• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat.Med. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses

tetano

Editor, Senior Moderator
Nat Immunol. 2019 Feb 11. doi: 10.1038/s41590-018-0305-x. [Epub ahead of print]
Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses.

Kanekiyo M[SUP]1[/SUP], Joyce MG[SUP]2,[/SUP][SUP]3[/SUP], Gillespie RA[SUP]2[/SUP], Gallagher JR[SUP]4[/SUP], Andrews SF[SUP]2[/SUP], Yassine HM[SUP]2,[/SUP][SUP]5[/SUP], Wheatley AK[SUP]2,[/SUP][SUP]6[/SUP], Fisher BE[SUP]2[/SUP], Ambrozak DR[SUP]2[/SUP], Creanga A[SUP]2[/SUP], Leung K[SUP]2[/SUP], Yang ES[SUP]2[/SUP], Boyoglu-Barnum S[SUP]2[/SUP], Georgiev IS[SUP]2,[/SUP][SUP]7[/SUP], Tsybovsky Y[SUP]8[/SUP], Prabhakaran MS[SUP]2[/SUP], Andersen H[SUP]9[/SUP], Kong WP[SUP]2[/SUP], Baxa U[SUP]8,[/SUP][SUP]10[/SUP], Zephir KL[SUP]2[/SUP], Ledgerwood JE[SUP]2[/SUP], Koup RA[SUP]2[/SUP], Kwong PD[SUP]2[/SUP], Harris AK[SUP]4[/SUP], McDermott AB[SUP]2[/SUP], Mascola JR[SUP]2[/SUP], Graham BS[SUP]11[/SUP].
Author information



Abstract

The present vaccine against influenza virus has the inevitable risk of antigenic discordance between the vaccine and the circulating strains, which diminishes vaccine efficacy. This necessitates new approaches that provide broader protection against influenza. Here we designed a vaccine using the hypervariable receptor-binding domain (RBD) of viral hemagglutinin displayed on a nanoparticle (np) able to elicit antibody responses that neutralize H1N1 influenza viruses spanning over 90 years. Co-display of RBDs from multiple strains across time, so that the adjacent RBDs are heterotypic, provides an avidity advantage to cross-reactive B cells. Immunization with the mosaic RBD-np elicited broader antibody responses than those induced by an admixture of nanoparticles encompassing the same set of RBDs as separate homotypic arrays. Furthermore, we identified a broadly neutralizing monoclonal antibody in a mouse immunized with mosaic RBD-np. The mosaic antigen array signifies a unique approach that subverts monotypic immunodominance and allows otherwise subdominant cross-reactive B cell responses to emerge.


PMID: 30742080 DOI: 10.1038/s41590-018-0305-x
 
Back
Top Bottom